A Single-Dose, Open-Label, Randomized, 4-Period, 5-Treatment Crossover Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 28 Oct 2013
Price : $35 *
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Pharmacokinetics
- 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jul 2013 New trial record
- 01 Jul 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.